Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $160,787 - $176,429
4,127 Added 1.69%
248,027 $10.1 Billion
Q1 2024

May 10, 2024

BUY
$40.88 - $43.27 $9.97 Million - $10.6 Million
243,900 New
243,900 $10.3 Billion

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Readystate Asset Management LP Portfolio

Follow Readystate Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Readystate Asset Management LP with notifications on news.